IMDNA develops custom qPCR and RT-qPCR research assays for targeted nucleic-acid detection, quantification, and gene-expression studies. Development can include target selection, sequence analysis, primer and hydrolysis-probe design, in-silico specificity review, multiplex architecture, fluorophore-channel planning, control strategy, reaction optimization, analytical performance evaluation, documentation, method transfer, and technical support.
Multiplex qPCR is not simply several singleplex assays combined into one tube. Each target can influence reaction kinetics, reagent competition, fluorescence separation, analytical sensitivity, specificity, and the behavior of the other assays in the same reaction. IMDNA approaches multiplex development as an integrated molecular system in which target biology, sequence conservation, oligonucleotide thermodynamics, instrument optics, reaction chemistry, controls, sample matrix, and intended research use are evaluated together.
A technically strong qPCR assay begins before primers are ordered. The first step is defining exactly what molecular event should be measured and which sequence architecture best represents that event.
Clarify whether the assay is intended to detect genomic DNA, RNA/cDNA, a transcript isoform, pathogen sequence, mutation, fusion junction, copy-number region, or other defined molecular target.
Review RefSeq/GenBank records, transcript structure, exon boundaries, polymorphisms, strain diversity, paralogs, pseudogenes, and related organisms or genes that may affect design.
Select an appropriate amplicon region, primer pair, probe location, fluorophore, internal control, and reaction format for the intended application.
Consider extraction method, expected nucleic-acid abundance, inhibitors, sample complexity, reverse-transcription strategy, and available input volume.
Define the analytical characteristics that matter for the research question, such as specificity, sensitivity, efficiency, dynamic range, precision, or multiplex equivalence.
Development can begin from a biological target, a published sequence, an investigator-provided primer/probe set, an existing assay requiring improvement, or a complete multiplex-panel concept.
Support selection of genes, variants, organisms, pathways, fusion transcripts, or molecular regions according to the research objective and available sequence evidence.
Use curated sequence records where practical and examine transcript variants, genomic context, conserved regions, sequence diversity, and relevant off-target sequences.
Develop candidate primer pairs considering specificity, melting behavior, amplicon size, GC composition, secondary structure, repetitive sequence, and compatibility with the intended reaction.
Design target-specific probes positioned within the amplicon and matched to the required fluorescence channel and multiplex configuration.
Use sequence-alignment and primer-specificity tools such as NCBI Primer-BLAST/BLAST to identify potential unintended amplification and relevant sequence homology before wet-lab testing.
For genetically variable targets, review sequence diversity and conserved regions to reduce avoidable loss of target coverage while maintaining specificity.
Evaluate each target independently before multiplex integration so fundamental problems are not hidden by multiplex interactions.
Evaluate primer/probe concentration, annealing/extension conditions, template input, master-mix compatibility, reaction volume, and other relevant variables.
Support design or selection of positive, negative, extraction/process, internal-amplification, endogenous, exogenous, or no-RT controls where scientifically appropriate.
Support studies of specificity, efficiency, linearity, precision, dynamic range, detection capability, interference, matrix behavior, and other characteristics relevant to the intended research use.
Prepare assay summaries, target maps, oligonucleotide documentation, optimization records, study protocols, data tables, troubleshooting notes, and transfer-support documents.
Support transfer of the developed assay to the customer's instrument, laboratory workflow, manufacturing format, or expanded research program.
IMDNA's development framework moves from sequence biology to experimentally demonstrated assay behavior and then to an integrated multiplex system.
NCBI Primer-BLAST combines Primer3 primer design with sequence-similarity searching to help identify primer pairs that are specific to the intended target. IMDNA uses the same underlying principle: assay design should be evaluated against the relevant sequence space rather than relying on primer thermodynamics alone.
Select a target region that is biologically appropriate, sufficiently conserved or variant-specific as required, and compatible with efficient real-time PCR amplification.
Assess primer binding against related genes, pseudogenes, paralogs, genomes, organisms, and other sequences likely to be present in the intended sample context.
Position the probe in a sequence region that contributes additional discrimination and is compatible with target diversity and intended multiplex architecture.
Review primer/probe melting behavior, GC content, hairpins, self-dimers, heterodimers, and other interactions that may impair amplification or multiplexing.
For RT-qPCR, consider exon structure, splice variants, genomic-DNA risk, exon-junction strategies, reverse-transcription method, and transcript abundance.
For sequence variants, consider the location of the variant relative to primer/probe binding and the discrimination required between reference and altered sequence.
For microbial targets, review available strain/genotype sequences to determine whether conserved regions adequately represent the intended target population.
Evaluate closely related organisms or sequences that should not generate signal and identify potential cross-reactivity risks before wet-lab confirmation.
CLSI MM17 recognizes multiplex nucleic-acid assays as analytically more complex than single-measurand assays and specifically addresses specimen preparation, multiplex technologies, reference/QC materials, data analysis, and performance evaluation. Multiplex architecture should therefore be designed as a system rather than assembled by combining individually successful assays without additional testing.
Assign fluorophores according to instrument optical channels, spectral separation, expected target abundance, dye brightness, and assay priority.
Consider whether very abundant and very low-abundance targets will coexist in the same reaction and whether competition may affect detection of weaker targets.
Review cross-dimer formation, complementary regions, nonspecific interactions, and the increased oligonucleotide complexity created by multiplexing.
Evaluate whether combined primers, probes, template loads, and amplification products alter reaction kinetics or reduce sensitivity compared with singleplex performance.
Compare target performance in multiplex and singleplex or lower-plex conditions to determine whether multiplexing materially changes expected behavior.
Integrate internal or process controls without allowing a high-copy control to dominate reaction resources or mask weak target performance.
Review channel cross-talk, spectral overlap, instrument calibration requirements, baseline behavior, and thresholding/analysis settings.
When the biology or instrument cannot support all targets in one reaction, organize targets into rational multi-reaction panels rather than forcing excessive plexing.
Prioritize analytically challenging targets during optimization so acceptable performance is not inferred only from the strongest targets in the panel.
Optimization is an iterative process. NIH/NCATS assay guidance emphasizes testing variables systematically and evaluating robustness, reproducibility, dynamic range, artifacts, and operational performance rather than maximizing signal alone.
A multiplex reaction should be treated as a new analytical configuration. Relevant characteristics may need to be re-evaluated after targets are combined.
MIQE 2.0, published in 2025, updates the widely used MIQE framework for transparent, technically sound qPCR research. For custom assay development, its principles are useful for structuring assay design, sample handling, controls, amplification performance, normalization, data analysis, and reporting.
| Performance Area | Molecular Question | IMDNA Development Approach |
|---|---|---|
| Specificity | Does the assay amplify the intended molecular target without unacceptable off-target signal? | Sequence screening, related-target challenge, negative materials, melt/amplicon review where relevant, and probe-supported specificity. |
| Amplification Efficiency | Does amplification behave consistently across the working concentration range? | Dilution-series evaluation, slope/efficiency review, reaction-condition optimization, and investigation of inhibition or competing reactions. |
| Linearity / Dynamic Range | Across what interval is the assay response technically useful? | Multi-level dilution studies with appropriate replicates and assessment of quantitative behavior or detection consistency. |
| Detection Capability | How reliably can low target levels be detected or quantified? | Low-level replicate studies using suitable reference or contrived materials and an endpoint appropriate to qualitative or quantitative use. |
| Precision | How reproducible is the result across replicates, runs, operators, instruments, or days? | Repeatability and broader reproducibility studies appropriate to the research objective. |
| Interference / Inhibition | Do sample components or competing targets alter assay performance? | Matrix comparisons, dilution behavior, internal controls, spike/recovery concepts, and targeted inhibitor/interference studies. |
| Multiplex Equivalence | Does target performance materially change when assays are combined? | Compare singleplex/lower-plex and final multiplex configurations, especially near challenging target concentrations. |
| Controls | Can the workflow detect extraction, amplification, contamination, or process failures? | Build a control architecture appropriate to the sample, method, and intended research workflow. |
Controls should be selected according to what can fail in the workflow. One universal control does not monitor every qPCR or RT-qPCR failure mode.
Confirms that the assay can generate the expected target-specific signal under the test conditions.
Helps identify contamination or nonspecific amplification arising from reagents or reaction setup.
Monitors sample processing or extraction when the experimental workflow requires confirmation that upstream processing occurred as intended.
Can help identify amplification failure or inhibition within an individual reaction when appropriately designed and balanced.
May support sample adequacy, input normalization, or biological normalization depending on the assay and scientific objective.
For applicable RT-qPCR gene-expression studies, helps evaluate whether genomic DNA contributes to observed signal.
Gene-expression assays require additional attention to RNA integrity, reverse transcription, transcript architecture, normalization, and biological interpretation. MIQE and MIQE 2.0 emphasize that normalization should be scientifically justified rather than assuming that one reference gene is stable under every biological condition.
Review isoforms, exon structure, transcript variants, pseudogenes, and genomic-DNA risk when selecting the amplicon.
Consider RNA integrity, extraction method, concentration, storage, contaminants, and reverse-transcription input when interpreting assay performance.
Match RT strategy to the study objective and maintain consistency because reverse-transcription variability can influence measured expression.
Evaluate candidate reference genes in the actual sample type and experimental condition rather than treating housekeeping genes as universally stable.
Support technically appropriate normalization and relative-expression analysis when assay efficiency and reference strategy justify the approach.
Develop targeted RT-qPCR assays to confirm selected expression findings from RNA sequencing, microarrays, or other transcriptomic studies.
Bacterial, viral, fungal, parasitic, veterinary, environmental, and other nucleic-acid targets with sequence-specific assay architecture.
Targeted RT-qPCR analysis of pathways, biomarkers, treatment response, inflammation, oncology, immunology, neuroscience, cardiovascular research, and other biological programs.
RT-qPCR assays designed across defined fusion junctions when sequence structure and intended research use support junction-specific detection.
Allele- or variant-focused qPCR strategies for defined sequence changes where qPCR provides adequate discrimination for the research question.
Relative qPCR approaches for selected genomic regions using appropriately characterized reference targets and experimental controls.
Multi-gene RT-qPCR panels designed around biological pathways rather than fixed catalog configurations.
Focused qPCR/RT-qPCR assays for verification of candidate biomarkers identified by discovery studies.
Single-target, multiplex, or multi-reaction panel configurations matched to the target number, instrument channels, biology, and study design.
Custom assay development is iterative. Unexpected results should be treated as technical information that helps identify weaknesses in sequence design, chemistry, controls, instrument settings, or sample workflow.
Investigate template quality, primer/probe sequence, reagent chemistry, annealing conditions, instrument configuration, target abundance, and inhibition.
Review low target abundance, extraction recovery, pipetting, template stability, reaction efficiency, inhibition, and run-to-run consistency.
Evaluate primer specificity, sequence homology, contamination, primer-dimer formation, annealing conditions, probe behavior, and analysis thresholds.
Compare singleplex and multiplex performance, then assess reagent competition, target abundance, primer/probe concentration, internal-control load, and channel assignment.
Review instrument optical compatibility, dye assignment, spectral overlap, calibration, fluorescence intensity, and thresholding.
Use dilution, internal controls, extraction comparisons, and appropriate reference materials to determine whether the sample matrix is limiting performance.
IMDNA provides scientific, technical, assay-development, optimization, QC/reference-material, documentation, method-transfer, troubleshooting, and non-regulatory research support based on the objectives of each customer project. Support may include target selection, sequence review, primer/probe design, in-silico specificity assessment, singleplex feasibility, multiplex architecture, fluorophore/channel planning, controls, optimization, analytical performance studies, troubleshooting, technical documentation, and transfer support.
Development strategy is customized to the intended research use, sample type, target biology, instrument, available sequence information, and requested assay format. Not every performance study or control described on this page is appropriate for every assay.
IMDNA does not represent a custom research assay as clinically validated, FDA cleared/approved, certified, or authorized for diagnostic use unless that status has been independently established through the applicable regulatory process. Research-use assay development, scientific consultation, analytical studies, and technical documentation do not themselves constitute regulatory authorization.
Where a laboratory intends to use a developed method for clinical testing, that laboratory is responsible for determining the applicable federal, state, local, accreditation, validation/verification, personnel, quality-system, and other requirements and for completing and documenting the studies required for its own intended use.
References to governmental, scientific, regulatory, standards-development, or professional organizations are provided for general informational purposes only and do not imply endorsement, approval, affiliation, certification, or sponsorship of IMDNA or its services.
The following resources support the molecular-design, qPCR-quality, multiplex-assay, sequence-specificity, and assay-optimization concepts used on this page. They are provided for independent scientific reference and do not imply endorsement of IMDNA.
Tell IMDNA about your target genes or organisms, biological question, sequence information, sample type, expected target abundance, instrument, available fluorescence channels, desired multiplex level, controls, and research objectives. Our scientific team can help develop a custom qPCR or RT-qPCR solution from target selection and primer/probe design through multiplex optimization, analytical evaluation, documentation, method transfer, and ongoing technical support.